Summary

The Middle East and Africa nucleic acid therapeutics, sport food additives and skin care market is expected to reach USD 1,184.56 million by 2032 from USD 725.48 million in 2024, growing with a substantial CAGR of 6.36% in the forecast period of 2025 to 2032.

Market Segmentation:
Middle East and Africa Nucleic Acid Therapeutics, Sport Food Additives and Skin Care Market, By Product (Nucleic Acid Therapeutic, Nucleic Acid Skin Care Products, and Nucleic Acid Sports Food Additives), Source (Natural Nucleic Acids and Synthetic Nucleic Acids), End User (Individual Consumers/ Home Healthcare, and Professional/Facility Use), Distribution Channel (Direct Tender, Retail Sales, and Others), Countries (U.A.E., Saudi Arabia, Qatar, South Africa, Kuwait, Egypt, Bahrain, Oman, and Rest of Middle East & Africa) - Industry Trends and Forecast to 2032


Overview for Middle East and Africa Nucleic Acid Therapeutics, Sport Food Additives and Skin Care Market Dynamics:

Driver
• Growing demand for functional foods, nutraceuticals, and bioactive skincare ingredients
Restraint
• High costs associated with production and research & development
Opportunity
• Breakthroughs in RNA and DNA-based therapies, food additives, and skincare innovations
Market Players:

The key players operating in the Middle East and Africa nucleic acid therapeutics, sport food additives and skin care market are:
• Pfizer Inc.
• Novartis AG
• AstraZeneca
• Biogen
• Juliette Armand

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 223
1.1 OBJECTIVES OF THE STUDY 223
1.2 MARKET DEFINITION 223
1.3 OVERVIEW 223
1.4 LIMITATIONS 226
1.5 MARKETS COVERED 226
2 MARKET SEGMENTATION 238
2.1 MARKETS COVERED 238
2.2 GEOGRAPHICAL SCOPE 239
2.3 YEARS CONSIDERED FOR THE STUDY 240
2.4 CURRENCY AND PRICING 240
2.5 DBMR TRIPOD DATA VALIDATION MODEL 241
2.6 MULTIVARIATE MODELING 244
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 245
2.8 DBMR MARKET POSITION GRID 246
2.9 DBMR VENDOR SHARE ANALYSIS 248
2.10 MARKET END USER COVERAGE GRID 250
2.11 SECONDARY SOURCES 252
2.12 ASSUMPTIONS 252
3 EXECUTIVE SUMMARY 253
4 PREMIUM INSIGHTS 258
4.1 PESTAL ANALYSIS 262
4.2 PORTER’S FIVE FORCES 263
4.2.1 THREAT OF NEW ENTRANTS 263
4.2.2 BARGAINING POWER OF BUYERS 264
4.2.3 BARGAINING POWER OF SUPPLIERS 264
4.2.4 THREAT OF SUBSTITUTES 264
4.2.5 COMPETITIVE RIVALRY 265
4.3 IMPORT EXPORT SCENARIO 266
4.4 PRICING ANALYSIS 267
4.5 PRODUCTION CAPACITY FOR TOP MANUFACTURERS 268
4.6 BRAND OUTLOOK 269
4.6.1 BRAND COMPARATIVE ANALYSIS OF MIDDLE EAST AND AFRICA NUCLEIC ACID SPORT FOOD ADDITIVES AND SKIN CARE MARKET 269
4.6.2 PRODUCT VS BRAND OVERVIEW 270
4.6.2.1 PRODUCT OVERVIEW 270
4.6.2.2 BRAND OVERVIEW 271
4.7 CONSUMER BUYING BEHAVIOUR FOR THE MIDDLE EAST AND AFRICA NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND MIDDLE EAST AND AFRICA NUCLEIC ACID SKIN CARE MARKET 272
4.7.1 AWARENESS AND EDUCATION 272
4.7.2 HEALTH AND PERFORMANCE-ORIENTED BUYERS 272
4.7.3 PREFERENCE FOR NATURAL AND SCIENTIFIC FORMULATIONS 272
4.7.4 PRICE SENSITIVITY AND WILLINGNESS TO PAY FOR QUALITY 273
4.7.5 ROLE OF BRAND TRUST AND REVIEWS 273
4.7.6 DIGITAL-FIRST SHOPPING EXPERIENCE 273
4.7.7 REGULATORY AND SAFETY CONCERNS 274
4.7.8 SUSTAINABILITY AND ETHICAL CONSIDERATIONS 274
4.8 FACTORS AFFECTING BUYING DECISION FOR MIDDLE EAST AND AFRICA NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND MIDDLE EAST AND AFRICA NUCLEIC ACID SKIN CARE MARKET 275
4.8.1 SCIENTIFIC VALIDATION AND EFFICACY 275
4.8.2 PRICE AND PERCEIVED VALUE 275
4.8.3 BRAND REPUTATION AND TRUST 275
4.8.4 PERSONAL HEALTH AND SKIN CONCERNS 276
4.8.5 DIGITAL INFLUENCE AND E-COMMERCE ACCESSIBILITY 276
4.8.6 REGULATORY APPROVALS AND SAFETY ASSURANCE 276
4.8.7 ETHICAL AND SUSTAINABILITY CONSIDERATIONS 277
4.8.8 AVAILABILITY AND CONVENIENCE 277
4.9 IMPACT OF ECONOMIC SLOWDOWN ON MIDDLE EAST AND AFRICA NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND MIDDLE EAST AND AFRICA NUCLEIC ACID SKIN CARE MARKET 278
4.9.1 IMPACT ON PRICE 278
4.9.2 IMPACT ON SUPPLY CHAIN 278
4.9.3 IMPACT ON SHIPMENT 278
4.9.4 IMPACT ON DEMAND 278
4.9.5 IMPACT ON STRATEGIC DECISIONS 279
4.10 PRODUCT ADOPTION SCENARIO FOR MIDDLE EAST AND AFRICA NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND MIDDLE EAST AND AFRICA NUCLEIC ACID SKIN CARE MARKET 280
4.10.1 AWARENESS AND MARKET PENETRATION 280
4.10.2 CONSUMER SEGMENTATION AND ADOPTION TRENDS 280
4.10.3 INFLUENCE OF SCIENTIFIC RESEARCH AND REGULATORY APPROVALS 281
4.10.4 PRICING, ACCESSIBILITY, AND DISTRIBUTION CHANNELS 281
4.11 RAW MATERIAL SOURCING ANALYSIS 283
4.11.1 SOURCES OF NUCLEIC ACIDS FOR FOOD ADDITIVES AND SKINCARE 283
4.11.2 SUPPLY CHAIN CHALLENGES IN RAW MATERIAL PROCUREMENT 283
4.11.3 QUALITY CONTROL AND REGULATORY COMPLIANCE 283
4.11.4 COST IMPLICATIONS OF RAW MATERIAL SOURCING 283
4.11.5 SUSTAINABILITY AND ETHICAL SOURCING 283
4.12 SUPPLY CHAIN ANALYSIS FOR MIDDLE EAST AND AFRICA NUCLEIC ACID SPORT FOOD ADDITIVES MARKET AND MIDDLE EAST AND AFRICA NUCLEIC ACID SKIN CARE MARKETS 285
4.13 OVERVIEW 285
4.13.1 LOGISTIC COST SCENARIO 285
4.13.2 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 285
4.14 PATENT ANALYSIS 286
4.15 PIPELINE 289
4.16 MERGERS & ACQUISITIONS 292
4.17 INDUSTRY INSIGHTS 293
5 PIPELINE ANALYSIS: 301
6 EPIDEMIOLOGY 307
6.1 INCIDENCE BY GENDER 307
6.2 TREATMENT RATES 307
6.3 MORTALITY RATES 307
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODELS 308
6.5 PATIENT TREATMENT SUCCESS RATES 308
7 REGULATORY COVERAGE 310
8 MARKET OVERVIEW 311
8.1 DRIVERS 313
8.1.1 GROWING DEMAND FOR FUNCTIONAL FOODS, NUTRACEUTICALS, AND BIOACTIVE SKINCARE INGREDIENTS 313
8.1.2 RISING INFLUENCE OF PERSONALIZED MEDICINE AND CUSTOMIZED SKINCARE SOLUTIONS 314
8.1.3 FAVORABLE REGULATORY POLICIES AND RISING R&D INVESTMENTS IN GENE-BASED THERAPIES 315
8.1.4 INCREASING PREVALENCE OF CHRONIC DISEASES AND AN AGING MIDDLE EAST AND AFRICA POPULATION 316
8.2 RESTRAINTS 318
8.2.1 INCREASING TREATMENT COSTS DUE TO HIGH PRODUCTION EXPENSES IN GENE-BASED THERAPIES 318
8.2.2 POTENTIAL RISKS AND SIDE EFFECTS OF GENE-BASED TREATMENTS 319
8.3 OPPORTUNITIES 320
8.3.1 BREAKTHROUGHS IN RNA AND DNA-BASED THERAPIES, FOOD ADDITIVES, AND SKINCARE INNOVATIONS 320
8.3.2 EXPANSION THROUGH STRATEGIC PARTNERSHIPS AND COLLABORATIONS 321
8.3.3 TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY SYSTEMS 322
8.4 CHALLENGES 324
8.4.1 LOW PUBLIC AWARENESS AND SLOW ADOPTION RATES 324
8.4.2 INTELLECTUAL PROPERTY COMPLEXITIES AND PATENT-RELATED HURDLES 325
9 MIDDLE EAST AND AFRICA NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY PRODUCT 326
9.1 OVERVIEW 327
9.2 NUCLEIC ACID THERAPEUTICS 328
9.2.1 BY CATEGORY 329
9.2.1.1 ANTISENSE 329
9.2.1.1.1 BY MOLECULES 329
9.2.1.1.1.1 NUSINERSEN 330
9.2.1.1.1.2 ETEPLIRSEN 330
9.2.1.1.1.3 GOLODIRSEN 330
9.2.1.1.1.4 INOTERSEN 330
9.2.1.1.1.5 VOLANESORSEN 330
9.2.1.1.1.6 OTHERS 330
9.2.1.1.2 BY DRUGS 330
9.2.1.1.2.1 SPINRAZA 330
9.2.1.1.2.2 EXONDYS 51 330
9.2.1.1.2.3 TEGSEDI 330
9.2.1.1.2.4 OTHERS 330
9.2.2 RNA INTERFERENCE 331
9.2.2.1 BY MOLECULES 331
9.2.2.1.1 VUTRISIRAN 331
9.2.2.1.2 GIVOSIRAN 331
9.2.2.1.3 PATISIRAN 331
9.2.2.1.4 LUMASIRAN 331
9.2.2.2 BY DRUGS 332
9.2.2.2.1 AMVUTRA 332
9.2.2.2.2 GIVLAARI 332
9.2.2.2.3 ONPATTRO 332
9.2.2.2.4 OXLUMO 332
9.2.2.3 BY TYPE 333
9.2.2.3.1 DOUBLE-STRANDED RNA VIRUSES (DSRNA) 333
9.2.2.3.2 SMALL INTERFERING RNA (SIRNA) 333
9.2.2.3.3 MICRORNAS (MIRNA) 333
9.2.3 CPG OLIGONUCLEOTIDES 334
9.2.3.1 BY TYPE 334
9.2.3.1.1 CPG ADJUVANTS IN VACCINES 334
9.2.3.1.2 TYPE B CPG OLIGONUCLEOTIDES 334
9.2.4 APTAMERS 334
9.2.5 OTHERS 334
9.2.6 BY STRUCTURE 335
9.2.6.1 SINGLE-STRANDED RNA 335
9.2.6.2 DOUBLE-STRANDED DNA 335
9.2.6.3 SINGLE-STRANDED DNA 335
9.2.6.4 SINGLE-STRANDED RNA/DNA 335
9.2.7 BY DRUG TYPE 336
9.2.7.1 MARKETED/ APPROVED DRUGS 336
9.2.7.1.1 SMALL NUCLEIC ACID DRUGS 336
9.2.7.1.2 MRNA VACCINES 336
9.2.7.1.3 OTHERS 336
9.2.7.2 PIPELINE DRUGS 336
9.2.8 BY APPLICATION 337
9.2.8.1 GENETIC DISORDERS 337
9.2.8.2 NEUROLOGICAL DISORDERS 337
9.2.8.3 INFECTIOUS DISEASES 337
9.2.8.4 AUTOIMMUNE DISEASES 337
9.2.8.5 OTHERS 337
9.2.9 BY ROUTE OF ADMINISTRATION 338
9.2.9.1 INTRATHECAL 338
9.2.9.2 SUBCUTANEOUS 338
9.2.9.3 INTRAVENOUS 338
9.2.9.4 OTHERS 338
9.3 NUCLEIC ACID SKIN CARE PRODUCTS 339
9.3.1 DNA-BASED SKIN CARE 340
9.3.1.1 DNA REPAIR SERUMS 340
9.3.1.1.1 ANTI-AGING DNA SERUMS 340
9.3.1.1.2 HYDRATING DNA SERUMS 340
9.3.1.1.3 DNA-BASED COLLAGEN-BOOSTING SERUMS 340
9.3.2 DNA-INFUSED MOISTURIZERS 341
9.3.2.1.1 DAY CREAMS 341
9.3.2.1.2 NIGHT CREAMS 341
9.3.2.1.3 DEEP HYDRATION CREAMS 341
9.3.2.1.4 OTHERS 341
9.3.2.2 DNA-BASED SUNSCREENS 341
9.3.2.2.1 BROAD-SPECTRUM UV PROTECTION 341
9.3.2.2.2 ANTI-PHOTOAGING DNA SUNSCREENS 341
9.3.2.3 DNA-BASED FACE MASKS 342
9.3.2.3.1 SHEET MASKS 342
9.3.2.3.2 CLAY MASKS 342
9.3.2.3.3 GEL MASKS 342
9.3.2.3.4 OTHERS 342
9.3.2.4 DNA-INFUSED EYE CREAMS 343
9.3.2.4.1 ANTI-DARK CIRCLE CREAMS 343
9.3.2.4.2 FINE LINE & WRINKLE REDUCTION CREAMS 343
9.3.2.4.3 PUFFINESS REDUCTION CREAMS 343
9.3.2.4.4 OTHERS 343
9.4 RNA-BASED SKIN CARE 344
9.4.1 RNA-INFUSED CREAMS 344
9.4.1.1 ANTI-AGING RNA CREAMS 344
9.4.1.2 BARRIER REPAIR CREAMS 344
9.4.1.3 INTENSIVE MOISTURE CREAMS 344
9.4.1.4 OTHERS 344
9.4.2 RNA-BASED ANTI-AGING TREATMENTS 345
9.4.2.1 WRINKLE REDUCTION FORMULATIONS 345
9.4.2.2 SKIN REJUVENATION TREATMENTS 345
9.4.2.3 OTHERS 345
9.4.3 GENE THERAPY-INFUSED SKIN CARE PRODUCTS 346
9.4.3.1 PERSONALIZED SKINCARE WITH DNA/RNA MODIFICATIONS 346
9.4.3.2 EPIGENETIC SKIN CARE TREATMENTS 346
9.4.3.3 OTHERS 346
9.4.4 BY SKIN TYPE 347
9.4.4.1 DRY SKIN 347
9.4.4.2 NORMAL SKIN 347
9.4.4.3 OILY SKIN 347
9.4.4.4 COMBINATION SKIN 347
9.4.4.5 SENSITIVE SKIN 347
9.4.4.6 OTHERS 347
9.4.5 BY PACKAGING 348
9.4.5.1 BOTTLES 348
9.4.5.1.1 SQUEEZE BOTTLES 348
9.4.5.1.2 PUMP BOTTLES 348
9.4.5.1.3 SPRAY BOTTLES 348
9.4.5.1.4 OTHERS 348
9.4.5.2 TUBES 349
9.4.5.2.1 TWIST CAPS 349
9.4.5.2.2 FLIP-TOP CAPS 349
9.4.5.2.3 AIRLESS SQUEEZE TUBES 349
9.4.5.2.4 OTHERS 349
9.4.5.3 DROPPER BOTTLES 350
9.4.5.3.1 PIPETTE DROPPERS 350
9.4.5.3.2 PUSH-BUTTON DROPPERS 350
9.4.5.4 JARS 350
9.4.5.4.1 SCREW-TOP LIDS 350
9.4.5.4.2 FLIP-TOP LIDS 350
9.4.5.4.3 SPATULA-INCLUDED JARS 350
9.4.5.4.4 OTHERS 350
9.4.5.5 AMPOULES 351
9.4.5.5.1 SINGLE-USE AMPOULES 351
9.4.5.5.2 MULTI-DOSE AMPOULES 351
9.4.5.6 SACHETS AND POUCHES 352
9.4.5.6.1 TEAR-OFF SACHETS 352
9.4.5.6.2 RESEALABLE POUCHES 352
9.4.5.7 OTHERS 352
9.4.6 BY PACKAGING SIZE 353
9.4.6.1 MEDIUM-SIZED PACKAGING (31 ML – 75 ML) 353
9.4.6.2 SMALL-SIZED PACKAGING (1 ML – 30 ML) 353
9.4.6.3 LARGE-SIZED PACKAGING (76 ML – 200 ML) 353
9.4.6.4 EXTRA-LARGE PACKAGING (ABOVE 200 ML) 353
9.4.7 BY PRICE RANGE 354
9.4.7.1 MASS 354
9.4.7.2 PREMIUM 354
9.4.7.3 LUXURY 354
9.4.8 BY APPLICATION 355
9.4.8.1 MOISTURIZATION & HYDRATION 355
9.4.8.1.1 DEEP HYDRATION WITH NUCLEIC ACIDS 356
9.4.8.1.1.1 DNA-BASED WATER-LOCK CREAMS 356
9.4.8.1.1.2 RNA-POWERED HYDRATION BOOSTERS 356
9.4.8.1.2 LONG-LASTING HYDRATION SERUMS 356
9.4.8.1.2.1 24-HOUR HYDRATION RNA SERUMS 356
9.4.8.1.2.2 DNA-POWERED MOISTURE-LOCKING TREATMENTS 356
9.4.8.1.3 SKIN BARRIER STRENGTHENING 357
9.4.8.1.3.1 NUCLEIC ACID-INFUSED CERAMIDE CREAMS 357
9.4.8.1.3.2 EPIGENETIC SKIN RESILIENCE ENHANCERS 357
9.4.8.2 SKIN REGENERATION & REPAIR 358
9.4.8.2.1 POST-SURGERY & INTENSIVE HEALING TREATMENTS 358
9.4.8.2.2 DNA-BASED WOUND HEALING CREAMS 358
9.4.8.2.3 RNA-INFUSED SCAR-REPAIR SERUMS 358
9.4.8.2.4 SKIN BARRIER RECOVERY FORMULATIONS 358
9.4.8.2.5 CELLULAR RENEWAL TREATMENTS 359
9.4.8.2.5.1 DNA-STIMULATING SKIN RENEWAL SERUMS 359
9.4.8.2.5.2 RNA-BASED ENZYMATIC SKIN REPAIR MASKS 359
9.4.8.2.6 DNA DAMAGE REPAIR 359
9.4.8.2.6.1 UV-INDUCED DNA DAMAGE REVERSAL CREAMS 359
9.4.8.2.6.2 EPIGENETIC REPAIR SERUMS 359
9.4.8.2.6.3 OTHERS 359
9.4.8.3 UV PROTECTION & SUN DAMAGE REPAIR 360
9.4.8.3.1 DNA-BASED SUNSCREENS 360
9.4.8.3.1.1 BROAD-SPECTRUM UVA/UVB PROTECTION 360
9.4.8.3.1.2 PHOTOAGING DEFENSE FORMULAS 360
9.4.8.3.2 AFTER-SUN DNA REPAIR TREATMENTS 361
9.4.8.3.2.1 DNA-INFUSED POST-SUN EXPOSURE MASKS 361
9.4.8.3.2.2 RNA-BASED SUNBURN RECOVERY GELS 361
9.4.8.3.3 BLUE LIGHT & POLLUTION PROTECTION 361
9.4.8.3.3.1 DNA-POWERED DIGITAL DEFENSE CREAMS 361
9.4.8.3.3.2 RNA-BASED ENVIRONMENTAL SHIELD SERUMS 361
9.4.8.4 ACNE & SCAR TREATMENT 362
9.4.8.4.1 DNA-BASED ACNE CONTROL SERUMS 362
9.4.8.4.1.1 ANTI-BACTERIAL NUCLEIC ACID SERUMS 362
9.4.8.4.1.2 SEBUM-REGULATING RNA TREATMENTS 362
9.4.8.4.2 RNA-POWERED SCAR FADING CREAMS 363
9.4.8.4.2.1 POST-ACNE MARK CORRECTORS 363
9.4.8.4.2.2 EPIGENETIC TISSUE REGENERATION SERUMS 363
9.4.8.4.3 HORMONAL ACNE TREATMENTS 363
9.4.8.4.3.1 DNA-BASED HORMONAL BALANCING SKINCARE 363
9.4.8.4.3.2 RNA-INFUSED ANTI-INFLAMMATORY GELS 363
9.4.8.4.4 OIL-CONTROL & PORE REDUCTION 364
9.4.8.4.4.1 DNA-POWERED OIL-BALANCING CREAMS 364
9.4.8.4.4.2 RNA-BASED PORE-TIGHTENING TONERS 364
9.4.8.5 HYPERPIGMENTATION & DARK SPOT TREATMENT 365
9.4.8.5.1 DARK SPOT CORRECTORS 365
9.4.8.5.1.1 DNA-BASED SPOT FADING TREATMENTS 365
9.4.8.5.1.2 RNA-POWERED DISCOLORATION REDUCERS 365
9.4.8.5.2 UNEVEN SKIN TONE CORRECTION 366
9.4.8.5.2.1 DNA-BASED SKIN BRIGHTENING MASKS 366
9.4.8.5.2.2 GENE-TARGETED EVEN SKIN TONE SOLUTIONS 366
9.4.8.5.3 MELANIN-INHIBITING SERUMS 366
9.4.8.5.3.1 DNA-BASED TYROSINASE INHIBITORS 366
9.4.8.5.3.2 RNA-POWERED BRIGHTENING SERUMS 366
9.4.8.5.4 POST-INFLAMMATORY HYPERPIGMENTATION (PIH) TREATMENTS 367
9.4.8.5.4.1 NUCLEIC ACID-INFUSED ACNE MARK CORRECTORS 367
9.4.8.5.4.2 RNA-BASED REDNESS-REDUCING CREAMS 367
9.4.8.6 ANTI-AGING & WRINKLE REDUCTION 368
9.4.8.6.1 COLLAGEN-BOOSTING FORMULATIONS 368
9.4.8.6.1.1 DNA-INFUSED COLLAGEN SERUMS 368
9.4.8.6.1.2 RNA-BASED PEPTIDE BOOSTERS 368
9.4.8.6.1.3 GENE-STIMULATING COLLAGEN MASKS 368
9.4.8.6.1.4 OTHERS 368
9.4.8.6.2 SKIN FIRMING & ELASTICITY IMPROVEMENT 369
9.4.8.6.2.1 DNA-BASED SKIN TIGHTENING SERUMS 369
9.4.8.6.2.2 RNA-POWERED ELASTICITY-ENHANCING CREAMS 369
9.4.8.6.2.3 NUCLEIC ACID-INFUSED FACIAL LIFTING MASKS 369
9.4.8.6.2.4 OTHERS 369
9.4.8.6.3 FINE LINE TREATMENT 370
9.4.8.6.3.1 FOREHEAD LINE CORRECTORS 370
9.4.8.6.3.2 CROW’S FEET REDUCTION CREAMS 370
9.4.8.6.3.3 UNDER-EYE WRINKLE SERUMS 370
9.4.8.6.3.4 NASOLABIAL FOLD TREATMENT 370
9.4.8.6.3.5 OTHERS 370
9.4.8.6.4 DEEP WRINKLE REPAIR 371
9.4.8.6.4.1 DNA-BASED RETINOL ALTERNATIVES 371
9.4.8.6.4.2 EPIGENETIC WRINKLE-REDUCING SERUMS 371
9.4.8.6.4.3 OTHERS 371
9.4.8.7 SENSITIVE SKIN CARE & INFLAMMATION REDUCTION 372
9.4.8.7.1 SOOTHING & ANTI-REDNESS FORMULATIONS 372
9.4.8.7.1.1 RNA-BASED ROSACEA TREATMENTS 372
9.4.8.7.1.2 DNA-INFUSED CALMING MASKS 372
9.4.8.7.2 HYPOALLERGENIC DNA-BASED SKINCARE 373
9.4.8.7.2.1 SENSITIVE SKIN RNA CREAMS 373
9.4.8.7.2.2 FRAGRANCE-FREE DNA SERUMS 373
9.4.8.7.3 ANTI-INFLAMMATORY NUCLEIC ACID TREATMENTS 373
9.4.8.7.3.1 DNA-POWERED CYTOKINE-REDUCING SERUMS 373
9.4.8.7.3.2 RNA-BASED IRRITATION-REDUCING GELS 373
9.5 NUCLEIC ACID SPORTS FOOD ADDITIVES 374
9.5.1 SPORTS SUPPLEMENTS 375
9.5.1.1 POWDER 375
9.5.1.2 CAPSULES 375
9.5.1.3 OTHERS 375
9.5.2 SPORTS FOOD 375
10 MIDDLE EAST AND AFRICA NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY SOURCE 376
10.1 OVERVIEW 377
10.2 NATURAL NUCLEIC ACIDS 378
10.2.1 PLANT-BASED 379
10.2.2 MARINE-DERIVED 379
10.2.3 OTHERS 379
10.3 SYNTHETIC NUCLEIC ACIDS 379
11 MIDDLE EAST AND AFRICA NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY END USER 380
11.1 OVERVIEW 381
11.2 INDIVIDUAL CONSUMERS/ HOME HEALTHCARE 382
11.2.1 WOMEN 383
11.2.2 MEN 383
11.2.3 UNISEX 383
11.3 PROFESSIONAL/FACILITY USE 383
11.3.1 DERMATOLOGY CLINICS 384
11.3.2 BEAUTY SALONS & SPAS 384
11.3.3 SPECIALTY CLINICS 384
11.3.4 HOSPITAL 384
11.3.5 OTHERS 384
12 MIDDLE EAST AND AFRICA NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY DISTRIBUTION CHANNEL 385
12.1 OVERVIEW 386
12.2 DIRECT TENDER 387
12.3 RETAIL SALES 388
12.3.1 BY TYPE 388
12.3.1.1 STORE BASED 389
12.3.1.1.1 SUPERMARKETS/HYPERMARKETS 389
12.3.1.1.2 SPECIALTY BEAUTY STORES 389
12.3.1.1.3 PHARMACIES & DRUGSTORES 389
12.3.1.1.4 DERMATOLOGY CLINICS & MEDICAL SPAS 389
12.3.1.1.5 TRAVEL RETAIL 389
12.3.1.1.6 OTHERS 389
12.3.1.2 NON STORE BASED 390
12.3.1.2.1 E-COMMERCE/PHARMACY WEBSITES 390
12.3.1.2.2 COMPANY-OWNED WEBSITES 390
12.4 OTHERS 390
13 MIDDLE EAST AND AFRICA NUCLEIC ACID THERAPEUTICS, SPORT FOOD ADDITIVES AND SKIN CARE MARKET, BY REGION 391
13.1 MIDDLE EAST & AFRICA 393
13.1.1 U.A.E. 418
13.1.2 SAUDI ARABIA 440
13.1.3 QATAR NUCLEIC 462
13.1.4 SOUTH AFRICA 485
13.1.5 KUWAIT 508
13.1.6 EGYPT 530
13.1.7 BAHRAIN 551
13.1.8 OMAN 573
13.1.9 REST OF MIDDLE EAST AND AFRICA 595
14 MIDDLE EAST AND AFRICA NUCLEIC ACID THERAPEUTICS MARKET, COMPANY LANDSCAPE 596
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 596
15 COMPANY PROFILES 597
15.1 PFIZER INC. 597
15.1.1 COMPANY SNAPSHOT 597
15.1.2 REVENUE ANALYSIS 597
15.1.3 COMPANY SHARE ANALYSIS 598
15.1.4 PRODUCT PORTFOLIO 598
15.1.5 RECENT DEVELOPMENTS 598
15.2 BIOGEN 599
15.2.1 COMPANY SNAPSHOT 599
15.2.2 RECENT FINANCIALS 599
15.2.3 COMPANY SHARE ANALYSIS 600
15.2.4 PRODUCT PORTFOLIO 600
15.2.5 RECENT DEVELOPMENTS/NEWS 600
15.3 ALNYLAM PHARMACEUTICALS, INC. 601
15.3.1 COMPANY SNAPSHOT 601
15.3.2 RECENT FINANCIALS 601
15.3.3 COMPANY SHARE ANALYSIS 602
15.3.4 PRODUCT PORTFOLIO 602
15.3.5 RECENT NEWS 603
15.4 SAREPTA THERAPEUTICS, INC. 604
15.4.1 COMPANY SNAPSHOT 604
15.4.2 REVENUE ANALYSIS 604
15.4.3 COMPANY SHARE ANALYSIS 605
15.4.4 PRODUCT PORTFOLIO 605
15.4.5 RECENT DEVELOPMENT 605
15.5 IONIS PHARMACEUTICALS, INC. 606
15.5.1 COMPANY SNAPSHOT 606
15.5.2 REVENUE ANALYSIS 606
15.5.3 COMPANY SHARE ANALYSIS 607
15.5.4 PIPELINE PRODUCT PORTFOLIO 607
15.5.5 RECENT DEVELOPMENTS 608
15.6 ASTRAZENECA 609
15.6.1 COMPANY SNAPSHOT 609
15.6.2 RECENT FINANCIALS 610
15.6.3 PIPELINE PRODUCT PORTFOLIO 610
15.6.4 RECENT DEVELOPMENT 612
15.7 MODERNA, INC. 613
15.7.1 COMPANY SNAPSHOT 613
15.7.2 RECENT FINANCIALS 613
15.7.3 PIPELINE PRODUCT PORTFOLIO 614
15.7.4 RECENT DEVELOPMENT 614
15.8 NOVARTIS AG 615
15.8.1 COMPANY SNAPSHOT 615
15.8.2 REVENUE ANALYSIS 616
15.8.3 PRODUCT PORTFOLIO 616
15.8.4 RECENT DEVELOPMENTS 617
15.9 SPARK THERAPEUTICS, INC. 618
15.9.1 COMPANY SNAPSHOT 618
15.9.2 PIPELINE PRODUCT PORTFOLIO 618
15.9.3 RECENT DEVELOPMENT 618
15.10 ZHEJIANG HAICHANG BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. 619
15.10.1 COMPANY SNAPSHOT 619
15.10.2 PIPELINE PRODUCT PORTFOLIO 619
15.10.3 RECENT DEVELOPMENT 620
16 MIDDLE EAST AND AFRICA NUCLEIC ACID SPORT FOOD ADDITIVES AND SKIN CARE MARKET: COMPANY LANDSCAPE 621
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 621
17 COMPANY PROFILES 622
17.1 REMY LAURE 622
17.1.1 COMPANY SNAPSHOT 622
17.1.2 COMPANY SHARE ANALYSIS 622
17.1.3 PRODUCT PORTFOLIO 623
17.1.4 RECENT DEVELOPMENT 623
17.2 NEOVA 624
17.2.1 COMPANY SNAPSHOT 624
17.2.2 COMPANY SHARE ANALYSIS 624
17.2.3 PRODUCT PORTFOLIO 625
17.2.4 RECENT DEVELOPMENT 628
17.3 MOONGLOW 629
17.3.1 COMPANY SNAPSHOT 629
17.3.2 COMPANY SHARE ANALYSIS 629
17.3.3 PRODUCT PORTFOLIO 630
17.3.4 RECENT DEVELOPMENT 633
17.4 THE NAKED CHEMIST 634
17.4.1 COMPANY SNAPSHOT 634
17.4.2 COMPANY SHARE ANALYSIS 634
17.4.3 PRODUCT PORTFOLIO 635
17.4.4 RECENT DEVELOPMENT 635
17.5 SKINSHIFT 636
17.5.1 COMPANY SNAPSHOT 636
17.5.2 COMPANY SHARE ANALYSIS 636
17.5.3 PRODUCT PORTFOLIO 637
17.5.4 RECENT DEVELOPMENT 638
17.6 BIO JOUVANCE PARIS CONSUMER 639
17.6.1 COMPANY SNAPSHOT 639
17.6.2 PRODUCT PORTFOLIO 639
17.6.3 RECENT DEVELOPMENT 639
17.7 DNA SKIN INSTITUTE 640
17.7.1 COMPANY SNAPSHOT 640
17.7.2 PRODUCT PORTFOLIO 640
17.7.3 RECENT DEVELOPMENT 641
17.8 JULIETTE ARMAND 642
17.8.1 COMPANY SNAPSHOT 642
17.8.2 PRODUCT PORTFOLIO 642
17.8.3 RECENT DEVELOPMENT 642
17.9 KALICHEM S.R.L. 643
17.9.1 COMPANY SNAPSHOT 643
17.9.2 PRODUCT PORTFOLIO 643
17.9.3 RECENT DEVELOPMENT 643
17.10 NIPPON PAPER INDUSTRIES CO., LTD. 644
17.10.1 COMPANY SNAPSHOT 644
17.10.2 REVENUE ANALYSIS 644
17.10.3 PRODUCT PORTFOLIO 645
17.10.4 RECENT DEVELOPMENT 645
17.11 POSTQUAM 646
17.11.1 COMPANY SNAPSHOT 646
17.11.2 PRODUCT PORTFOLIO 646
17.11.3 RECENT DEVELOPMENT 649
17.12 SHOPATDNA.COM 650
17.12.1 COMPANY SNAPSHOT 650
17.12.2 PRODUCT PORTFOLIO 650
17.12.3 RECENT DEVELOPMENT 651
18 QUESTIONNAIRE 652
19 RELATED REPORTS 655